AgomAb Therapeutics NV AGMB
Updated: 9 Aug 2026
No signal published yet
We already track AgomAb Therapeutics NV and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow AgomAb Therapeutics NV? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow AgomAb Therapeutics NV free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, Agomab reported its financial results for the first half of 2026 and confirmed its outlook for the remainder of the year. The company announced regulatory alignment with the U.S. FDA on the Phase 2b NOV-ERA study design for ontunisertib in fibrostenosing Crohn's disease. Cash and cash investments stood at 252 million euros as of June 30, 2026, which management expects to fund operations into the first half of 2029.
What Firelda Watch includes for AgomAb Therapeutics NV
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow AgomAb Therapeutics NV? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow AgomAb Therapeutics NV free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more